Office of Grant Writing & Publications.

NCI Cancer Immunotherapy Trials Network (CITN) (U01)

Office of Grant Writing & Publications

202 Jesse Hall
University of Missouri
Columbia, MO 65211

573 882-9500 phone
573 884-8371 fax

Limited Submission Announcement

The National Cancer Institute (NCI) invites applications for the Cancer Immunotherapy Trials Network (U01). The purpose of this Funding Opportunity Announcement (FOA) is to stimulate the conduct of early (Phase I and Phase II) clinical trials in the area of cancer immunotherapy by forming a Cancer Immunotherapy Trials Network (CITN). The emphasis is on clinical trials of "high-priority" agents that were identified at the 2007 NCI immunotherapy agent workshop and on clinical trials using combinations of immunotherapy modalities and other agents.

The CITN will support a multi-investigator team assembled to bring new immunotherapy agents to the clinic. This support will be realized through a single award for a Central Operations and Statistical Center (COSC) of the CITN. Whereas this FOA solicits applications specifically for the CITN COSC, the awardee team and their program directors/principal investigators (PDs/PIs) will provide overall leadership and statistical and protocol coordinator support for the CITN program. COSC applicants must plan that the CITN will include the following additional elements: (1) up to 25 institutions that will conduct the clinical trials as CITN "Member Sites" (supported through subcontracts within the COSC award); (2) support for tumor immunology laboratories that are associated with the Member Sites to conduct standardized immunomonitoring assays and biomarker and correlative studies related to the clinical trials; and (3) a data coordinating service that will be provided by a unit operated by the NCI (which remains beyond the scope of solicited applications).

Because MU is limited to one application for this program, letters of intent must be submitted to the Office of Research,, no later than 4:00 p.m. on Friday, January 15, 2010. Letters of intent should be limited to three pages and should include 1) a summary of the overall research strategies and plans for the conduct of immunotherapy trials in the CITN, 2) a summary of past performance and PI qualifications in the context of managing multi-institutional cancer clinical trials in the area of immunotherapies, and 3) a plan for project oversight and communication with collaborative site members.


Up to $5,200,000. The total project period may not exceed five years. The budget should not exceed $1.6 million total costs in the first two years of the award and $3.6 million in years three through five.

MU Deadline:

Friday, January 15, 2010

Sponsor Deadlines:

Optional letter of intent due January 19, 2010
Full proposals due by February 19, 2010


URL for more information:

All limited submission announcements can be tracked by deadline via the Calendar at or by announcement date via the Limited Submissions listing at